SCHEMBL13816489

SCHEMBL13816489

CCNC(=O)c1ccc(C(=O)c2cc(CC(=O)OC)ccc2OC)c(N)c1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 5/20 0.44
▸ ALDH1A1 P00352 3/20 0.43
▸ GAA P10253 1/20 0.43
▸ GFER P55789 1/20 0.43
▸ MAPT P10636 2/20 0.42
▸ TP53 P04637 1/20 0.42
▸ NR1H4 Q96RI1 1/20 0.41
▸ HTT P42858 2/20 0.41
▸ L3MBTL1 Q9Y468 2/20 0.41
▸ PTGDR2 Q9Y5Y4 2/20 0.41
▸ TSHR P16473 2/20 0.39
▸ CYP1A2 P05177 2/20 0.39
▸ CYP3A4 P08684 2/20 0.39
▸ BLM P54132 1/20 0.39
▸ PTGDR Q13258 1/20 0.39
▸ ALOX15 P16050 1/20 0.39
▸ GLA P06280 1/20 0.39
▸ CYP2C19 P33261 1/20 0.39
▸ MAPK1 P28482 1/20 0.39
▸ NPC1 O15118 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13816480 0.84 ALDH1A1 (0.50) LMNAALDH1A1GAAMAPTTSHR
SCHEMBL13816512 0.83 PTGDR2 (0.48) LMNAALDH1A1GAAGFERMAPT
SCHEMBL13816424 0.79 ALDH1A1 (0.51) LMNAALDH1A1GAAGFERMAPT
SCHEMBL14310352 0.77 ALOX15 (0.41) LMNAALDH1A1GAAGFERMAPT
SCHEMBL13816538 0.74 L3MBTL1 (0.47) LMNAALDH1A1MAPTTP53NR1H4
SCHEMBL13816495 0.73 PTGDR2 (0.59) PTGDR2PTGDR
SCHEMBL13816305 0.73 MAPT (0.56) LMNAALDH1A1GAAGFERMAPT
SCHEMBL2546019 0.72 HTR4 (0.56) LMNAALDH1A1MAPTTP53NR1H4
SCHEMBL7247237 0.72 ALDH1A1 (0.69) LMNAALDH1A1GAAGFERMAPT
SCHEMBL13816477 0.71 PTGDR2 (0.71) PTGDR2PTGDR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7541383-B2 Asthma and allergic inflammation modulators AMGEN INC. (US) 2009-06-02 — — US disclosed
US-7541383-B2 Asthma and allergic inflammation modulators AMGEN INC. (US) 2009-06-02 — — US disclosed
US-20080085891-A1 Asthma and allergic inflammation modulators FU ZICE 2008-04-10 — — US disclosed
US-20080085891-A1 Asthma and allergic inflammation modulators FU ZICE 2008-04-10 — — US disclosed
US-7321001-B2 Asthma and allergic inflammation modulators AMGEN INC. (US) 2008-01-22 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080085891-A1 Asthma and allergic inflammation modulators IL5, TSLP, CYSLTR2 LMNA 4770/4885ALDH1A1 763/4885GAA 3555/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback